Baxter (NYSE: BAX) reported Q1 EPS of $0.93, $0.13 better than the analyst estimate of $0.80. Revenue for the quarter came in at $3.7 billion versus the consensus estimate of $3.68 billion.

GUIDANCE:

Baxter sees FY2022 EPS of $4.12-$4.20, versus the consensus of $4.29.

Baxter sees Q2 2022 EPS of $0.86-$0.89, versus the consensus of $0.98.

• For full-year 2022: Baxter now expects U.S. GAAP earnings of $2.35 to $2.43 per diluted share and adjusted earnings, before special items, of $4.12 to $4.20 per diluted share. The company expects sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency basis and approximately 3% on an operational basis. Baxter’s updated full-year financial outlook reflects the impact from higher oil prices, ongoing supply chain challenges causing increased inflationary pressures as well as the removal of any contribution from the Novum IQ infusion system.
• For second-quarter 2022: The company expects sales growth of approximately 26% on a reported basis, 29% to 30% on a constant currency basis and approximately 4% on an operational basis. The company expects U.S. GAAP earnings of $0.48 to $0.51 per diluted share and adjusted earnings, before special items, of $0.86 to $0.89 per diluted share.

For earnings history and earnings-related data on Baxter (BAX) click here.